ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................JBDM Ver 2.0.24 - 2999001/03514235KORRIGIERTE EUROPÄISCHE PATENTSCHRIFTB8B120240214W173deBibliographieenBibliographyfrBibliographieEP18152422.4201801182020012420200221dedede2024021420240720190724201930202401032024012023102520240214202407C12N 15/113 20100101AFI20180530BHEP A61K 31/7088 20060101ALI20180530BHEP A61P 1/00 20060101ALI20180530BHEP C12N 15/113 20130101 FI20180518BHEP C12N 15/1136 20130101 LI20180518BHEP C12N2310/127 20130101 LA20180518BHEP deZUSAMMENSETZUNG ZUR BEHANDLUNG EINES AN COLITIS ULCEROSA LEIDENDEN PATIENTEN SOWIE VERWENDUNG DER ZUSAMMENSETZUNG ALS ARZNEIMITTELenCOMPOSITION FOR THE TREATMENT OF A PATIENT SUFFERING FROM ULCERATIVE COLITIS AND UTILISATION OF SAID COMPOSITION AS MEDICAMENTfrCOMPOSITION DESTINÉE AU TRAITEMENT DE PATIENTS SOUFFRANT D'UNE COLITE ULCEREUSE AINSI QUE L'UTILISATION DE LADITE COMPOSITION EN TANT QUE MÉDICAMENTWO-A1-2017/205506WO-A2-2005/033314WO-A2-2014/040891US-A1- 2003 040 497POPP VANESSA ET AL: "Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, Bd. 152, Nr. 1, 14. September 2016 (2016-09-14), Seiten 176-192, XP029851140, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2016.09.005Anonymous: "DRKS-ID: DRKS00007193 SB012 for the Treatment of Active Ulcerative Colitis (SECURE): a Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy, Pharmacokinetics, Tolerability, and Safety of SB012 Enema Administered Once Daily", , 9. Juni 2015 (2015-06-09), XP055476967, Gefunden im Internet: URL:http://www.drks.de/drks_web/navigate.d o?navigationId=trial.HTML&TRIAL_ID=DRKS000 07193 [gefunden am 2018-05-18]WEIGMANN BENNO ET AL: "Suppression of Experimental Ulcerative Colitis by Topical Delivery of Specific Dnazyme Blocking Thetranscription Factor GATA3", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, 22. April 2017 (2017-04-22), XP085104521, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(17)32631-8KATRINA RAY: "A role for GATA3 in ulcerative colitis", NATURE REVIEWS / GASTROENTEROLOGY & HEPATOLOGY, Bd. 13, Nr. 11, 5. Oktober 2016 (2016-10-05), Seiten 624-624, XP55476486, US ISSN: 1759-5045, DOI: 10.1038/nrgastro.2016.163ALESYA A. FOKINA ET AL: "Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials", EXPERT OPINION ON DRUG DELIVERY, Bd. 14, Nr. 9, 7. Dezember 2016 (2016-12-07), Seiten 1077-1089, XP55476495, GB ISSN: 1742-5247, DOI: 10.1080/17425247.2017.1266326URBANSKA ALEKSANDRA M ET AL: "What's Next for Gastrointestinal Disorders: No Needles?", JOURNAL OF CONTROLLED RELEASE, Bd. 221, 2. Dezember 2015 (2015-12-02), Seiten 48-61, XP029383249, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.11.031Zhijie Xu ET AL: "Small-molecule Nucleic-acid-based Gene-silencing Strategies" In: "Nucleic Acids - From Basic Aspects to Laboratory Tools", 16. März 2016 (2016-03-16), InTech, XP55476951, ISBN: 978-953-51-2264-7 DOI: 10.5772/62137, * Tabelle 2 *HOLGER GARN ET AL: "GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy", EUROPEAN JOURNAL OF IMMUNOLOGY, Bd. 47, Nr. 1, 2. Dezember 2016 (2016-12-02), Seiten 22-30, XP055476945, ISSN: 0014-2980, DOI: 10.1002/eji.201646450COMINELLI FABIO ET AL: "Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?", CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY JUL 2017, vol. 4, no. 1, July 2017 (2017-07), pages 19-32, ISSN: 2352-345XKOELINK PJ AND TE VELDE AA: "Mistakes in mouse models of IBD and how to avoid them.", UEG EDUCATION, vol. 16, 2016, pages 11-14,NGUYEN THI LOAN ANH ET AL: "How informative is the mouse for human gut microbiota research?", DISEASE MODELS & MECHANISMS JAN 2015, vol. 8, no. 1, January 2015 (2015-01), pages 1-16, ISSN: 1754-8411ALDARS-GARCÍA LAILA ET AL: "The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review.", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 17 MAR 2021, vol. 22, no. 6, 17 March 2021 (2021-03-17) , ISSN: 1422-0067CROUWEL FEMKE ET AL: "Gut microbiota-driven drug metabolism in inflammatory bowel disease.", JOURNAL OF CROHN'S & COLITIS 11 JUL 2020, 11 July 2020 (2020-07-11), ISSN: 1876-4479VALATAS VASSILIS ET AL: "The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY DEC 2013, vol. 305, no. 11, December 2013 (2013-12), pages G763-G785, ISSN: 1522-1547VICTOR JULIAN ET AL: "Inability of DNAzymes to cleave RNA in vivo is due to limited Mg[Formula: see text] concentration in cells.", EUROPEAN BIOPHYSICS JOURNAL : EBJ MAY 2018, vol. 47, no. 4, May 2018 (2018-05), pages 333-343, ISSN: 1432-1017TRAPANI VALENTINA ET AL: "Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel.", INFLAMMATORY BOWEL DISEASES 15 09 2018, vol. 24, no. 10, 15 September 2018 (2018-09-15), pages 2198-2210, ISSN: 1536-4844SWANSON KENNETH D ET AL: "Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.", CURRENT OPINION IN GASTROENTEROLOGY 11 2018, vol. 34, no. 6, November 2018 (2018-11), pages 384-391, ISSN: 1531-7056Renz, JonasHöchlstr. 381675 MünchenDESterna Biologicals GmbH102025158SCR19P02EP1Rudolf-Bultmann-Str. 4h35039 MarburgDEPharma Patents International AG101562763Leonhardsgraben 52 Postfach4001 BaselCHALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR